Download - Valvular heart disease
David L. Rutlen, M.D.10 July 2014
1
2
Natural History of Aortic Stenosis
Outcome of 622 Adults with Asymptomatic Hemodynamically Significant Aortic Stenosis
During Prolonged Follow Up
622 PatientsAge 72 ± 11 yearsPeak systolic velocity ≥ 4 m/sAt 5 years only 25% alive and without surgery11 patients died suddenly without surgery or symptoms ~ 1 % per yearalthough no follow up for ≥ 1 year in 5 of 11
2005; 111; 3290-3295 3
4
Copyright ©2007 American Heart Association
Operative Risk Stratification and Predictors for Long-Term Outcome: A Multicenter Study using
Dobutamine Stress Hemodynamics
6 centers, 136 patientsAortic valve area 0.7 cm² (0.6 – 0.8)Transaortic gradient 29 mm Hg (23 – 34)Cardiac index 2.11 L/min/m² (1.75 – 2.55)Contractile reserve assessed during dobutamine
group 1: 92 patients, present stroke volume increased 33%
(26-46%) group 2: 44 patients, absent stroke volume increased 10% (2
– 13%)
2003: 108: 319-3245
6
7
Outcome after Aortic Valve Replacement for Low-Flow/Low-Gradient Aortic Stenosis without
Contractile Reserve on Dobutamine Stress Echocardiography
81 symptomatic patientsAVA ≤ 1 cm ², LV EF ≤ 40%
No increase stroke volume ≥ 20% with dobutamine
J Am Coll Cardiol 2009; 53: 1865-1873
8
Prognostic Impact of AVR in LGAS Patients Without CR on DSE: Matched Population
9
Transcatheter Aortic-Valve Implantation for Inoperable Aortic Stenosis
•358 Patients with severe aortic stenosis• Aortic valve area <0.8 cm²• Mean aortic valve gradient ≥ 40 mm Hg• Peak aortic jet velocity ≥ 4.0 m/sec
•≥50% Predicted probability• 30 day death or serious irreversible
condition
•Randomized: 179/179• Standard therapy including aortic
valvuloplasty• Transfemoral transcatheter implantation
balloon – expandable bovine pericardial valve
N. Engl J. Med 2012; 366: 1696-1704
10
11
12
13
14
15
Two-Year Mortality, Stratified According to the Society of Thoracic Surgeons (STS) Risk Score.
16
Two-Year Mortality, Stratified According to the Society of Thoracic Surgeons (STS) Risk Score.
17
Two-Year Mortality, Stratified According to the Society of Thoracic Surgeons (STS) Risk Score.
Two-Year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement
699 patients with severe aortic stenosis > 15% predicted probability 30 day death randomized:
TAVR: 244 transfemoral
104 transapicalSurgical replacement: 351
42 did not receive assigned therapy4 in TAVR group38 in surgery group
N. Engl J. Med 2012: 366: 1686-9518
19
20
Transcatheter Aortic – Valve Replacement with a Self-Expanding Prosthesis
•795 Patients with severe aortic stenosis
• aortic valve area ≤ 0.8 cm²
• mean aortic valve gradient > 40 mm Hg
• peak aortic jet velocity ≥ 4.0 m/sec
•risk of death within 30 days after surgery ≥ 15%
•risk of death or irreversible complications within 30 days < 50%
•Randomized• 394 TAVR• 401 surgical AVR
N. Engl. J. Med. 2014; 370: 1790-1798
21
Kaplan-Meier Cumulative Frequency of Death from Any Cause.
22
Intervene Aortic Stenosis
Class I1.Severe AS (Vmax > 4 m/s) with symptoms2.Severe AS, LVEF < 50%3.Severe AS, undergoing other cardiac surgeryClass II (a)1.Very severe AS (Vmax > 5 m/s), low surgical risk2.Severe AS, decreased exercise tolerance or exercise fall in BP3.Symptomatic patients with low flow/low gradient severe AS4.Moderate AS (Vmax 3.0-3.9 m/s) undergoing other cardiac surgeryClass II (b)1.Severe AS, rapid progression, low surgical risk
AHA/ACC Guidelines March 2014
Copyright ©2007 American Heart Association
Natural History of Asymptomatic Patients with Aortic Regurgitation and Normal
Left Ventricular Function77 asymptomatic patientsNormal LVEF63 patients : 3-4 + AR14 patients : pulse pressure > 70 mm HgFollow-up 49 months (6-114)Events : development sxs LVEF ≤ 0.50No patients died12 patients underwent aortic valve replacement
Onset sxs: 11 patients Onset LV dysfunction: 1 patient
1983; 68; 509-517 23
Copyright ©2007 American Heart Association
1983; 68; 509-517 (cont) 24
Copyright ©2007 American Heart Association
1983; 68; 509-517 (cont) 25
Copyright ©2007 American Heart Association
1983; 68; 509-517 (cont) 26
27
Intervene Aortic Regurgitation
Class I1.Severe AR with symptoms2.Severe AR with LVEF < 50%3.Severe AR, undergoing other cardiac surgeryClass II (a)1.Severe AR with LVESD > 50 mm2.Moderate AR, undergoing other cardiac surgeryClass II (b)1. Severe AR with LVEDD > 65mm if surgical risk low
AHA/ACC Guidelines March 2014
28
Late Results of Percutaneous Mitral Commissurotomy
Bichat University Hospital and Pitie-Sulpetriere Hospital 1986-1995
1024 patients
Good functional resultsno cv deathno interventionNYHA I or II
Circulation 2012; 125:2119-2127
29
30
Intervene Mitral Stenosis
Class I1.Percutaneous commissurotomy for severe MS (MVA ≤ 1.5 cm2) with symptoms2.Mitral surgery for severe MS if symptoms severe and not candidate for commissurotomy3.Severe MS, undergoing other cardiac surgeryClass II (b) Percutaneous commissurotomy for severe MS with new AF
AHH/ACC Guidelines March 2014
31
Survival Implication of Left Ventricular End-Systolic Diameter in Mitral Regurgitation dueto Flail Leaflets
registry: 4 European & 1 U.S.Center 739 patients1980-2004medical management: 187medical and surgical management 552
J am coll cardiol 2009; 54: 1961-1968
32
Overall survival according to left ventricular end-systolic diameter (LVESD) in patients with organic mitral regurgitation (MR): (A) conservative management
33
Overall survival according to left ventricular end-systolic diameter (LVESD) in patients with organic mitral regurgitation (MR): (B) medical and surgical treatment
34
Adjusted post-operative overall survival according to LVESD in operated patients with organic MR.
35
Recovery of Left Ventricular Function after Surgical Correction of Mitral Regurgitation caused by Leaflet Prolapse
Mayo Clinic1063 patients underwent mitral surgery
924 repair139 replacement
1980-2000
J. Thorac Cardiovascular Surgery 2009; 137:1071-1076
36
37
Pulmonary hypertension adversely affects short- and long-term survival after mitral valve operation for mitral regurgitation
University of Maryland Medical Center 873 consecutive patients underwent mitral surgery2002-2010Pulmonary hypertension: systolic pulmonary artery pressure none: sPAP< 40 mm Hg mild: 40 ≤ sPAP < 50 mm Hg moderate: 50 ≤ sPAP < 60 mm Hg severe: sPAP ≥ 60 mm Hg
J Thorac Cardiovasc Surg 2011; 142: 1439-1452
38
Hospital mortality according to opreoperative PH grade (P< .0001). PH, Pulmonary hypertension.
39
Long-term survival according to preoperative PH. B, Survival according to preoperative PH grade.
40
Comparison of Early Surgery versus Conventional Treatment in Asymptomatic Severe Mitral Regurgitation
Asan Medical Center, Seoul, Korea447 Consecutive Asymptomatic Patients Observed preserved LVEF, Severe MR enrolled 1996-2005 early surgery 161, conventional 286 similar age, gender, euro SCORE, LVEF end point: operative mortality, cardiac death,
repeat mitral valve surgery, CHF admission
Circulation 2009; 119:797-804
41
Comparison of event-free survival rates between the operated (OP) and conventional treatment (CONV) groups in propensity-matched pairs.
42
Should Patients with Severe Degenerative Mitral Regurgitation Delay Surgery Until Symptoms Develop
Cleveland Clinic registry4,586 patientsPrimary mitral valve repair or replacement1985-2008
Ann Thorac Surg 2010; 90:481-488
unadjusted
Survival According to NYHA Class
propensity matched
Survival According to NYHA Class
46
Association Between Early Surgical Intervention vs Watchful Waiting and Outcomes for Mitral Regurgitation due to Flail Mitral Leaflets
6 centers Europe and U.S.1980 – 20041021 patients
575 initial medical management446 mitral valve surgery within 3 months
enrollment
JAMA 2013:310(6): 609-616
47
Overall
48
Propensity Matched
49
Overall
50
Propensity matched
51
Valve Repair Versus Valve Replacement for Denegerative Mitral Valve Disease
Cleveland Clinic3286 Patients Undergo Primary Mitral Surgery1985-2005
J Thorac Cardiovasc Surg 2008; 135: 885-893
52
UNADJUSTED SURVIVAL
53
PROPENSITY MATCHED SURVIVALBlue=repairRed=replacementGreen=age, gender matched US population
54
REOPERATION IN PROPENSITY MATCHED Blue=repair
Red=replacement with bioprosthesis Black=replacement with mechanical valve
55
Long-Term Survival of Patients Undergoing Mitral Valve Repair and Replacement: A Longitudinal Analysis of Medicare Fee-for-Service Beneficiaries
47,279 fee for service beneficiaries Primary isolated mitral valve repair or replacement2000-2009Annual mitral procedure volume determined >40 cases per year ≤ 40 cases per year
Circulation 2013:1870-1876
Ten-year survival for Medicare fee-for-service beneficiaries undergoing mitral valve repair and replacement from 2000 through 2009 compared with expected survival in the age- and sex-matched
US population.
Vassileva C M et al. Circulation. 2013;127:1870-1876
Copyright © American Heart Association, Inc. All rights reserved.
57
Longitudinal Outcome of Isolated Mitral Repair in Older Patients
Linked Society of Thoracic Surgeons and Centers for Medicare and Medicaid Services databases14,604 isolated non-emergent primary mitral repairs1991-2007Mean age 73 years
Ann Thorac Surg 2012; 94:1870-1879
58
Operative Mortality
Avoidance of mitral reoperation
Ten-year survival after isolated primary mitral valve (MV) repair in patients aged 65 years or more.
61
Percutaneous Repair or Surgery for Mitral Regurgitation
37 Centers in U.S. and Canada2005-2008279 patients 3+ or 4+ chronic mitral regurgitation
symptomatic: LVEF > 25% and LVESD < 55 mmasymptomatic: LVEF 25-60%, LVESD 40-55, new
AF or PAH malcoaptation middle scallops anterior and
posterior leafletsrandomized 2:1 percutaneous repair or conventional surgery
N Engl J Med 2011; 364: 1395 - 1406
62
63
Percutoneous Repair vs Standard Surgery
12 months
Efficacy 55% 73% P=0.007 death 6% 6% surgery 20% 2% P< 0.001 3+ or 4+ MR 21% 20%
30 days
Major adverse events 15% 48% P < 0.001
difference due to mechanical ventillation > 48 hourstransfusion ≥ 2 units blood
percutaneous standard
64
Intervene Primary Mitral RegurgitationClass I1.Severe MR with symptoms and LVEF > 30%2.Severe MR and LVEF 30-60% or LVESD ≥ 40 mm3.Repair in preference to replacement when severe MR limited to posterior leaflet4.Repair in preference to replacement when severe MR involves just anterior leaflet or both leaflets if durable repair can be accomplished5.Severe MR undergoing other cardiac surgeryClass II a1.Repair for severe MR
a. new onset AFb. PA systolic pressure > 50 mm Hg
Class II b1.transcatheter repair NYHA Class III – IV, severe MR, prohibitive surgical risk
AHA/ACC Guidelines March, 2014
65
Independent Prognostic Value of Functional Mitral Regurgitation in Patients with Heart Failure: 1256 Patients with Ischaemic and non-ischaemic Cardioneyopathy
Retrospective review 4 Italian centersQuantitative assessment MREnd-point: mortality & hospitalization for CHFEnd-point correlated with degree of MR
independent of LVEF and restrictive mitral filling
Heart 2011; 97: 1675 - 1680
66years
67
68
69
Impact of Mitral Valve AnnuloplastyCombined with Revascularization in Patients with Functional Mitral Regurgitation
Cleveland Clinic, 390 patients, 1991-20033 - 4+ ischemic MR undergoing CABG290 mitral annuloplasty100 no mitral annuloplastyAnnuloplasty improved early symptoms
J am coll cardiol 2007; 49: 2191 - 2201
70
Survival Ater CABG Either Alone or With Concomitant MV Annuloplasty for Functional Ischemic MR
Unadjusted
71
Survival Ater CABG Either Alone or With Concomitant MV Annuloplasty for Functional Ischemic MR
Propensity matched
72
73
Influence of Mitral Regurgitation Repair on Survival in the Surgical Treatment for Ischemic Heart Failure Trial
99 world wide sites, LVEF ≤ 35%1212 patients randomized: medicine vs CABG18% moderate or severe MR
Circulation 2012; 125: 2639-2648
74
Years Following Randomization
75
Coronary Artery Bypass Surgery with or without Mitral Valve Annuloplasty in moderate Functional Ischemic Mitral Regurgitation
6 centers in U.K., 1 in Poland73 patients referred for CABG
moderate ischemic MRLVEF > 30%
Randomized: CABG + annuloplasty (34) CABG (39)
1 year follow up
Circulation 2012; 126:2502-2510
76
77
Surgical Revascularization is Associated with Maximal Survival in Patients with Ischemic Mitral Regurgitation
Duke University Medical Center1990-2009, 4989 patients, retrospective significant coronary artery disease moderate or severe mitral regurgitation
Circulation 2014; 1229: 2547-2556
Adjusted survival curves by treatment category
Castleberry A W et al. Circulation. 2014;129:2547-2556
Copyright © American Heart Association, Inc. All rights reserved.
79
Intervene Chronic Severe Secondary Mitral Regurgitation
Class II (a)Undergoing CABG or AVRSeverely symptomatic (NYHA Class III or IV)Class II (b)Repair for moderate MR undergoing other cardiac surgery
AHA/ACC Guidelines, March 2014
80
END